GLOSSARY OF TERMS FOR FDA'S RARE DISEASE DAY 2022

TERM	DEFINITION
Adverse Event	Adverse event is any unfavorable experience associated with the use
	of a medicine in a patient. Adverse events can range from mild to
	severe. Serious adverse events are those that can cause disability, are
	life-threatening, result in hospitalization or death, or are birth
	defects.
Biological Product	Biological products include a wide range of products such as vaccines,
	blood and blood components, allergenics, cells, gene therapy, tissues,
	and recombinant therapeutic proteins. Biologics are isolated from a
	variety of natural sources — human, animal, or microorganism — and
	may be produced by biotechnology methods and other cutting-edge
	technologies. Gene-based and cellular biologics, for example, are at
	the forefront of biomedical research and may be used to treat a
	variety of medical conditions with unmet needs.
BLA	Biologic License Application – a submission to FDA to commercialize a
	biological product. It contains specific information on the
	manufacturing processes, chemistry, pharmacology, clinical
	pharmacology and the medical effects of the product.
CBER	Center for Biologics Evaluation and Research - advances the public
	health by ensuring that biological products are safe and effective and
	available to those who need them. See (1) in FDA Organizational Chart
	below.
CDER	Center for Drug Evaluation and Research - performs an essential
	public health task by ensuring that safe and effective drugs are
	available to improve the health of people in the US. CDER regulates
	over-the-counter and prescription drugs, including biological
	therapeutics and generic drugs. See (2) in FDA Organizational Chart
	below.
CDRH	Center for Devices and Radiological Health - has responsibility for
	protecting and promoting the public health through the approval of
	safe and effective medical devices. See (3) in FDA Organizational
	Chart below.

Clinical Danafit	A thoropoutio intervention may be said to confer elivital houseful if it
Clinical Benefit	A therapeutic intervention may be said to confer clinical benefit if it
	prolongs life, improves function, and/or improves the way a patient
	feels.
Clinical Trial	An investigation or research that involves one or more human subjects,
Clinical Investigation	undertaken to assess the safety or effectiveness of a drug, biologic, or
Clinical Study	medical device.
СОА	Clinical outcome assessment - assessment of a clinical outcome can be
	made through report by a clinician, a patient, a non-clinician observer
	or through a performance-based assessment. There are four types of
	COAs:
	(1) patient-reported outcome (PRO)
	(2) clinician-reported outcome (ClinRO) measures
	(3) observer-reported outcome (ObsRO), and
	(4) performance outcome (PerfO).
Compliance	Adherence to all the trial-related requirements, good clinical practice
(in relation to clinical trials)	(GCP) requirements, and applicable federal and local laws and policies.
Confidentiality	The practice of maintaining as private all information related to clinical
(regarding study participants)	trial participants, including their personal identity and all personal
	medical information. Results from the study will usually be presented
	in terms of trends or overall findings and will not mention any specific
	participants.
Control group	The group of participants that receives standard treatment or a
	placebo. The control group may also be made up of healthy volunteers.
	Researchers compare results from the control group with results from
	the experimental group to understand treatment effect of an
	investigational product.
Digital Health	Health technologies including categories such as mobile health
	(mHealth), health information technology (IT), wearable devices,
	telehealth and telemedicine, and personalized medicine. Examples
	include mobile medical apps and software that support clinical
	decisions to artificial intelligence and machine learning.
Endpoint	Principal indicator(s) used for assessing the primary question (i.e.,
	hypothesis) of a clinical trial. A variable that pertains to the efficacy or
	safety evaluations of a trial.

Equipoise	The ability of a study to ensure balance, in that it is based on an ethical
Equipoise	principle that there is not a better treatment available.
HDE	Humanitarian Device Exemption - a marketing application for an HUD
	(see below) – the legal criterion for approval is reasonable assurance
	of safety and probable benefit
HUD	Humanitarian Use Device - a medical device intended to benefit
	patients in the treatment or diagnosis of a disease or condition that
	affects or is manifested in not more than 8,000 individuals in the US
	per year
IDE	Investigational Device Exemption - A request from a clinical study
	sponsor to obtain authorization from FDA to administer an
	investigation device to humans.
Inclusion/Exclusion Criteria	The medical or other guidelines that determines whether a person may
	or may not be allowed to enter a clinical trial. These criteria are based
	on such factors as age, gender, the type and stage of a disease,
	previous treatment history, and other medical conditions. The criteria
	are used to identify appropriate participants for the trial. Also known
	as Eligibility or Enrollment Criteria.
Informed Consent Form	A process used by researchers to communicate to potential and
	enrolled participants the risks and potential benefits of participating in a clinical study. When a participant provides informed consent, it
	means that he or she has learned the key benefits and risks about a
	research study and agrees to take part in it.
In vitro	In glass, as in a test tube. An in vitro test is one that is done in glass or
	plastic vessels in the laboratory. In vitro is the opposite of in vivo.
In vivo	In the living organism. For example, an experiment that is done in vivo
	is done in the body of a living organism. In vivo is the opposite of in
	vitro.
IND	Investigational New Drug: A request from a sponsor to obtain
	authorization from the FDA to administer an investigational drug or
	biological product to humans.
Investigator	Investigator is an individual who actually conducts a clinical
	investigation (i.e., under whose immediate direction the drug is
	administered or dispensed to a subject). In the event an investigation

	to conduct a second of the birth of the birth of the second of the birth of the bir
	is conducted by a team of individuals, the investigator is the
	responsible leader of the team. "Subinvestigator" includes any other
	individual member of that team.
IRB	Institutional Review Board - Any board, committee, or other group
	formally designated by an institution to review, to approve the
	initiation of, and to conduct periodic review of, biomedical research
	involving human subjects. The primary purpose of such review is to
	assure the protection of the rights and welfare of the human subjects.
	Also known as Ethics Committee (EC).
Medical Device	An instrument, apparatus, implement, machine, contrivance, implant,
	in vitro reagent, or other similar or related article, including any
	component part, or accessory, which is –
	(1) recognized in the official National Formulary, or the United
	States Pharmacopeia, or any supplement to them,
	(2) intended for use in the diagnosis of disease or other
	conditions, or in the cure, mitigation, treatment, or prevention
	of disease, in man or other animals, or
	(3) intended to affect the structure or any function of the body
	of man or other animals, and
	which does not achieve its winners intended assumptions through
	which does not achieve its primary intended purposes through
	chemical action within or on the body of man or other animals and
	which is not dependent upon being metabolized for the achievement
	of its primary intended purposes.
Natural History Study	A study in which the investigator collects information about the natural
	history of a disease in the absence of an intervention, from the
	disease's onset until either its resolution or the individual's death.
NCTR	National Center for Toxicological Research – the only FDA Center
	located outside the Washington D.C. metropolitan area (located in in
	Jefferson, Arkansas) - provides interdisciplinary toxicology research
	solutions and consultations that support and anticipate future FDA
	needs to guard and improve personal and public health. See (6) in FDA
	Organizational Chart below.

NDA	New Drug Application – submission through which sponsors formally
	propose that the FDA approve a new pharmaceutical for sale and
	marketing in the US. The goals of the NDA are to provide enough
	information to permit an FDA review team to reach the following key
	decisions:
	(1) Whether the drug is safe and effective in its proposed use(s),
	and whether the benefits of the drug outweigh the risks.
	(2) Whether the drug's proposed labeling (package insert) is
	appropriate, and what it should contain.
	(3) Whether the methods used in manufacturing the drug and the
	controls used to maintain the drug's quality are adequate to
	preserve the drug's identity, strength, quality, and purity.
OCE	Oncology Center of Excellence - helps expedite development of
	medical products for oncologic and hematologic malignancies
	(cancers) and supports an integrated approach to their clinical
	evaluation. See (4) in FDA Organizational Chart below.
"Off Label Use"	When an FDA-approved medical product is used for a use that has not
	been approved by FDA. Also called unapproved use of an approved
	product.
Orphan Drug/Product	Products developed diagnosis, prevention, mitigation, treatment or
	cure of rare diseases.
Outcome	Events or experiences measured in the context of a study because they
	may be influenced by the research intervention or exposure.
Patient Engagement	Involves meaningful involvement of patients throughout the product
	development process from the initial design to the implementation of
	the trial and the dissemination of the study results. The goal is to
	improve clinical trials by making them more patient-centric and
	relevant to patient values.
Patient registry	A type of observational study that collects information about patients'
	medical conditions and/or treatments to better understand how a
	condition or treatment affects patients in the real world.
PFDD	Patient-focused drug development - systematic approach to help
	ensure that patients' experiences, perspectives, needs, and priorities
	are captured and meaningfully incorporated into the development and


	evaluation of medical products throughout the medical product life
	cycle.
PRO	Patient-Reported Outcome - An outcome based on a report that comes directly from the patient about the status of a patient's health condition without amendment or interpretation of the patient's response by a clinician or anyone else. Symptoms or other unobservable concepts known only to the patient are measured by
	PRO measures. PROs can also assess the patient perspective on
	functioning or activities that may also be observable by others. See also
	COA definition above.
Placebo	An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
Protocol	The written description of a clinical study. It includes the study's objectives, design, and methods.
Randomized Controlled Trial (RCT)	 A study in which the act of assigning or ordering subjects to treatments and placebo is determined by machine and not determined by the investigators. The purpose of the randomized controlled trial is to: (1) to guard against any use of judgment or systematic arrangements leading to one treatment getting preferential assignment, i.e., to avoid bias; (2) to provide a basis for the standard methods of statistical analysis such as significance tests.
Real-World Data (RWD)	Data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.
Real-World Evidence (RWE)	The clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data.
Repurposing	Identification of potential novel uses or indications of existing marketed or unmarketed drugs.
Review	The basis of FDA's decision to approve an application. It is a comprehensive analysis of clinical trial data and other information prepared by FDA drug application reviewers. A review is divided into sections on medical analysis, chemistry, clinical pharmacology, biopharmaceutics, pharmacology, statistics, and microbiology.

Sponsor	A person who takes responsibility for and initiates a clinical investigation. The sponsor may be an individual or pharmaceutical company, governmental agency, academic institution, private organization, or other organization. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator.
Study Design	The investigative methods and strategies used in the clinical study.
Subject/Participant	An individual who participates in a clinical trial either as a recipient of the investigational product(s) or as a control. A subject may be a healthy volunteer or a patient.
Underserved Population	Populations whose voices and needs may be overlooked. This population includes the economically disadvantaged, racial and ethnic minorities, the uninsured, rural residents, children and the elderly.

Glossary Sources:

ClinicalTrials.gov Glossary of Common Site Terms FDA Glossary of Clinical Trial Terms Code of Federal Regulations (CFR) §312.3

FDA Organizational Chart



Department of Health and Human Services Food and Drug Administration

February 17, 2022